YolTech Therapeutics has announced the successful enrollment of the inaugural patient in the Phase I clinical trial of YOLT-201.

Olatec Therapeutics, Inc., a pioneer in the field of selective NLRP3 inhibitors, revealed that individuals with type 2 diabetes mellitus and associated diabetic complications are currently being recruited

Vivani Medical, Inc., a pioneering company in biopharmaceuticals, revealed plans to commence the inaugural clinical trial for the NPM-115 initiative in Australia.

Pfizer have chosen the preferred once-daily modified release form of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.

This submission seeks regulatory approval through the Therapeutic Goods Administration (TGA)’s Clinical Trial Notification scheme to initiate a first-in-human Phase 1 clinical trial for SAT-3247.

Context Therapeutics Inc. has publicized the acquisition of CT-95, previously the property of Link Immunotherapeutics, Inc.

Skyhawk Therapeutics Reports Positive Topline Results from Phase 1 Trial of SKY-0515 for Huntington’s Disease, Achieving 72% Reduction in Huntingtin mRNA.

MEKanistic Therapeutics Inc.’s innovative dual-target therapy, MTX-531, shows considerable tolerability and sustained tumor reduction in preclinical cancer studies.

Rgenta Therapeutics secures FDA nod for IND application of RGT-61159, an oral RNA modulator intended to stop MYB production, targeting Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC).

Avalo Therapeutics Reports IND Activation for AVTX-009, an anti-IL-1β Antibody, Aimed at Treating Hidradenitis Suppurativa.

uniQure Releases Promising Interim Results Showing Reduced Disease Progression in Phase I/II AMT-130 Trials for Huntington’s Disease.

The agreement specifies that the Phase 2 clinical trial will evaluate the effectiveness of PRT37890, a new and highly selective SMARCA2 degrader, and Merck's KEYTRUDA in treating cancers with SMARCA4 mutations.